EP2491167A2 - Methods of depositing discrete hydroxyapatite regions on medical implants - Google Patents
Methods of depositing discrete hydroxyapatite regions on medical implantsInfo
- Publication number
- EP2491167A2 EP2491167A2 EP10773461A EP10773461A EP2491167A2 EP 2491167 A2 EP2491167 A2 EP 2491167A2 EP 10773461 A EP10773461 A EP 10773461A EP 10773461 A EP10773461 A EP 10773461A EP 2491167 A2 EP2491167 A2 EP 2491167A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- electrolyte solution
- calcium
- phosphate
- electrical potential
- implant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D9/00—Electrolytic coating other than with metals
- C25D9/04—Electrolytic coating other than with metals with inorganic materials
- C25D9/08—Electrolytic coating other than with metals with inorganic materials by cathodic processes
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D5/00—Electroplating characterised by the process; Pretreatment or after-treatment of workpieces
- C25D5/18—Electroplating using modulated, pulsed or reversing current
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D5/00—Electroplating characterised by the process; Pretreatment or after-treatment of workpieces
- C25D5/48—After-treatment of electroplated surfaces
-
- C—CHEMISTRY; METALLURGY
- C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
- C25D—PROCESSES FOR THE ELECTROLYTIC OR ELECTROPHORETIC PRODUCTION OF COATINGS; ELECTROFORMING; APPARATUS THEREFOR
- C25D5/00—Electroplating characterised by the process; Pretreatment or after-treatment of workpieces
- C25D5/60—Electroplating characterised by the structure or texture of the layers
- C25D5/615—Microstructure of the layers, e.g. mixed structure
- C25D5/617—Crystalline layers
Definitions
- the present technology relates to medical implants having discrete regions of a calcium phosphate (e.g., hydroxyapatite), and methods of their manufacture.
- a calcium phosphate e.g., hydroxyapatite
- CPP calcium phosphate phase
- Hydroxyapatite is a biocompatible material similar in composition to the mineral content of natural bone.
- hydroxyapatite coatings on medical orthopedic implants can enhance the implant's osteoconductive potential, among other things.
- CPP coatings can be deposited onto electroconductive, or metal substrates using solution-based techniques, such as electrochemical deposition or sol-gel deposition.
- One advantage of using such deposition processes is that they are not "line of sight" processes and thus can provide a complete coating coverage of complex shaped substrates. With the use of implants having nano-scale texturing, however, such deposition processes can be disadvantageous in that the coating may be applied over the nano-scale texturing, thereby negating its affect. Accordingly, there remains a need to provide methods for using electrochemical deposition techniques to provide discrete regions of CPP, including hydroxyapatite.
- the present technology provides methods for electrochemically depositing one or more discrete regions of a calcium phosphate onto a medical implant.
- the implant has at least one area having an electroconductive surface. At least a portion of the electroconductive surface is contacted with an electrolyte solution comprising calcium ions and phosphate ions. An electrical potential is applied between the electroconductive surface and the electrolyte solution. A plurality of discrete regions of a calcium phosphate phase is formed onto the electroconductive surface, wherein the calcium phosphate phase comprises a needle-shaped morphology.
- the method for electrochemically depositing discrete regions of a calcium phosphate phase onto a medical implant includes providing an implant including at least one area having a metallic surface.
- At least a portion of the metallic surface is contacted with an electrolyte solution comprising calcium ions and phosphate ions.
- the metallic surface is used as a cathode, and an electrical potential is applied between the cathode and the electrolyte solution.
- the electrical potential is applied with a constant current density of from about 10 to about 50 mA/cm for a period of time of between about 1 to about 20 minutes.
- a plurality of discrete regions of needle-shaped hydroxyapatite crystals is electrochemically deposited onto the metallic surface.
- the present technology also provides processes for making a plurality of medical implants having discrete regions of calcium phosphate phase.
- Such processes include preparing an electrolyte solution comprising calcium ions and phosphate ions having a concentration ratio of calcium:phosphate of about 1.7: 1.
- a plurality of implants is placed into the electrolyte solution, wherein each implant comprises at least one area having an electroconductive surface.
- the electroconductive surfaces are used as cathodes and an electrical potential is applied between the cathodes and the electrolyte solution, wherein the electrical potential has a constant current density of from about 10 to about 50 mA/cm .
- the electrical potential can be applied for a period of time of between about 1 to about 20 minutes.
- the process includes electrochemically depositing a plurality of discrete regions of needle-shaped hydroxyapatite crystals onto the electroconductive surfaces.
- Figure 1 is a SEM micrograph magnified about 80,000x illustrating discrete regions of hydroxyapatite deposited on a titanium substrate and having a needlelike morphology
- Figures 2 and 3 are SEM micrographs magnified about 10,000x illustrating discrete regions of hydroxyapatite deposited on a titanium substrate having a needle-like morphology.
- the word "include,” and its variants, is intended to be non-limiting, such that recitation of items in a list is not to the exclusion of other like items that may also be useful in the materials, compositions, devices, and methods of this technology.
- the terms “can” and “may” and their variants are intended to be non-limiting, such that recitation that an embodiment can or may comprise certain elements or features does not exclude other embodiments of the present technology that do not contain those elements or features.
- compositions or processes specifically envisions embodiments consisting of, and consisting essentially of, A, B and C, excluding an element D that may be recited in the art, even though element D is not explicitly described as being excluded herein.
- compositional percentages are by weight of the total composition, unless otherwise specified. Disclosures of ranges are, unless specified otherwise, inclusive of endpoints. Thus, for example, a range of "from A to B" or “from about A to about B” is inclusive of A and of B. Disclosure of values and ranges of values for specific parameters (such as temperatures, molecular weights, weight percentages, etc.) are not exclusive of other values and ranges of values useful herein. It is envisioned that two or more specific exemplified values for a given parameter may define endpoints for a range of values that may be claimed for the parameter.
- Parameter X is exemplified herein to have value A and also exemplified to have value Z, it is envisioned that Parameter X may have a range of values from about A to about Z.
- disclosure of two or more ranges of values for a parameter (whether such ranges are nested, overlapping or distinct) subsume all possible combination of ranges for the value that might be claimed using endpoints of the disclosed ranges.
- Parameter X is exemplified herein to have values in the range of 1 - 10, or 2 - 9, or 3 - 8, it is also envisioned that Parameter X may have other ranges of values including 1 - 9, 1 - 8, 1 - 3, 1 - 2, 2 - 10, 2 - 8, 2 - 3, 3 - 10, and 3 - 9.
- the present technology provides methods for electrochemically depositing discrete regions of a calcium phosphate phase onto a medical implant.
- Titanium and its alloys, in addition to other metal substrates, are becoming increasingly popular as implant materials due to their favorable biocompatibility and favorable mechanical and chemical properties.
- Calcium phosphate phases (CPP) have a lot of bioactive potential, thus enabling chemical bonding to natural bone.
- the main inorganic constituent CPP may contain amorphous calcium phosphate (Ca 9 (P0 4 )6 ⁇ nH 2 0), hydroxyapatite (Ca 1 o(P0 4 )6(OH) 2 ), octacalcium phosphate (CagH 2 (PO) 6 H 2 0), or brushite (CaHP0 4 ⁇ 2H 2 0), or mixtures thereof.
- the CPP can additionally be doped with ions such as fluoride, silver, magnesium, carbonate, strontium, or sodium.
- hydroxyapatite (Ca 10 (PO 4 ) 6 (OH) 2 ) is a CPP biocompatible material that is similar in composition to the major inorganic mineral content of natural bone.
- hydroxyapatite coatings provided on metallic or otherwise electroconductive medical implants can enhance an implant's osteoconductivity potential.
- Common deposition techniques for coating hydroxyapatite onto implants can include plasma spray coating, electrochemical deposition, and sol-gel deposition. While plasma spray coating is a widely used method, its high process conditions (high temperature) can result in coating properties that deviate from the mineral phase of bone, especially with respect to crystal structure and solubility.
- the high process temperatures may cause partial decomposition of hydroxyapatite, resulting in the formation of other CPP, including amorphous calcium phosphate (ACP), a-tricalcium phosphate (TCP), ⁇ -TCP, tetracalcium phosphate, and calcium oxide.
- ACP amorphous calcium phosphate
- TCP a-tricalcium phosphate
- ⁇ -TCP ⁇ -TCP
- tetracalcium phosphate calcium oxide
- One problem with the known deposition techniques is the time required in order to obtain a crystalline hydroxyapatite structure, having needle-like morphology, from an amorphous precursor that is formed and subsequently changed into a crystalline material, mimicking in vivo mineralization process.
- spheres begin to grow at energetically favored places, commonly identified as the "ACP phase.”
- the ACP is then transformed to the crystalline phase of hydroxyapatite.
- small calcium phosphate precursor island regions are first formed that coalesce and form a continuous, homogeneous pre-layer on the metal surface. Both the pre-layer and the spheres comprise clusters of Ca 3 (P0 4 ) 2 from which preferential crystalline hydroxyapatite needles grow:
- a more efficient means of hydroxyapatite deposition may include the direct deposition of hydroxyapatite crystalline onto a metal substrate, or a more timely transformation to the crystalline phase.
- Such a direct application can be beneficial where surfaces of the implant include nano-scale texturing or etching.
- the present technology provides an electrochemical deposition process to facilitate an early transition from ACP to discrete deposition regions of hydroxyapatite crystalline, without the formation of a continuous layer of ACP as one would expect with such a deposition process. Unless one painstakingly masks various areas of the implant prior to the treatment, the typical electrochemical deposition process will first provide a continuous coating layer over the entire implant that is subsequently transformed into hydroxyapatite. Such a continuous coating would likely negate the various benefits obtained from any nano-scale etching or texturing.
- the present technology surprisingly provides the electrochemical deposition of discrete regions of CPP, and hydroxyapatite in particular, onto the surface of a medical implant.
- the present technology affects the kinetics of reaction, which can be controlled with the appropriate electrochemical parameters, as discussed below.
- it provides a CPP deposition that is predominantly needle-shaped hydroxyapatite after only a short duration of time.
- from about 70 to about 90 percent, or from about 85 to about 90 percent of the discrete CPP regions may have a crystalline structure, while only from about 10 to about 30 percent of the CPP may be an amorphous phase.
- This can provide for calcium phosphate regions of variable solubility.
- it may be preferred that the hydroxyapatite has a random orientation.
- a medical implant including at least one area having an electroconductive surface.
- the electroconductive surface can be a discrete area or it can be a continuous area covering the surface of the entire implant.
- the surface can be provided with nano-scale texturing, if desired.
- Such an electroconductive surface can comprise a material selected from the group consisting of titanium, a titanium alloy, titanium nitrate, a CoCrMo alloy, stainless steel, an electroconductive polymer, and mixtures thereof.
- the electrochemical deposition can be carried out in an electrolysis cell, or bath, in which the implant, as least the metallic or otherwise electroconductive surface, is cathodically polarized.
- a three-electrode arrangement can be made including a calomel electrode used as a reference electrode, a platinum sheet or gauze used as the counter electrode, and the metallic implant provided as the cathode.
- the deposition process can take place biomimetically, near physiological pH and temperature conditions.
- the electroconductive surface is placed in contact with an electrolyte solution comprising calcium ions and phosphate ions.
- the electrolyte can comprise a Ca 2+ /H x P0 4 (3 x)" containing solution.
- the ratio of the concentration of the calcium ions and the phosphate ions is chosen such that it is equal or at least equivalent to their concentrations in hydroxyapatite.
- the electrolyte solution may include calcium chloride, calcium chloride dihydrate, or calcium acetate as the source of calcium ions, and ammonium dihydrogen phosphate as the source of phosphate ions. The choice of the particular salts used may be based on availability.
- the electrolyte solution is prepared using solutions that correspond to a final concentration of calcium:phosphate of about 1.7: 1 (e.g., 1.67: 1).
- a final concentration of calcium:phosphate of about 1.7: 1 e.g., 1.67: 1.
- various embodiments currently provide for a standard-like concentration of calcium ions of about 1.7 mM (e.g., 1.7 mM) and a concentration of phosphate ions of about 1.0 mM.
- concentration may call for the electrical potential to be applied for from about 1 to about 5 minutes, preferably about 2.5 minutes, in order to obtain desired deposition.
- an addition modification includes applying the electrical potential having a similar current density for a slightly longer period of time. With such a lower concentration of ions, the electrical potential can be applied for from about 1 to about 20 minutes, or from about 5 to about 15 minutes, such as about 10 minutes, in order to obtain desired deposition.
- the current density will still be applied at about the same level, or slightly lower, as will be discussed. It should be understood that the actual current density required may vary for each different type of component processed, and may depend upon the total surface area and surface finish, as well as the power sources available.
- an electrical potential is applied between the electroconductive surface and the electrolyte solution.
- the present technology provides applying an electrical potential having a constant current density of from about 10 to about 50 mA/cm for a period of time of from about 1 to about 20 minutes.
- the electrical potential can be applied having a constant current density of from about 20 to about 40 mA/cm for a period of time of from about 2 to about 10 minutes.
- a high flux of ions rapidly moves toward the cathode and a plurality of discrete regions of a calcium phosphate phase are deposited on the electroconductive surface of the implant.
- heterogeneous nucleation or precipitation may occur within the solution near the implant surface that additionally settles on the implant surface.
- the present technology provides beginning with an electrolyte solution containing calcium and phosphate ions and leading to the predominant electrochemical deposition of highly desirable hydroxyapatite crystalline having needle-shaped morphology on the surface of an implant.
- the hydroxyapatite is deposited as homogeneous and discrete island type regions.
- an implant includes any nano- scale texturing, it is not covered by a complete coating of an amorphous calcium phosphate phase, as it would be with conventional electrochemical deposition techniques.
- the morphology of the hydroxyapatite crystals can be visually described as needle-like or needle-shaped, and in various embodiments having needles with dimensions of less than about 500 nm in length and less than about 60 nm in width, and in some embodiments less than about 30 nm in width.
- Typical needle lengths may be from about 200 and about 300 nm in certain embodiments, or from about 90 and about 140 nm in other embodiments.
- Electrochemical deposition of a calcium phosphate phase depends in part on the pH-dependent solubility of the calcium phosphate, which has been found to decrease with increasing pH.
- electrochemical deposition process one can control the pH at the cathode/electrolyte interface.
- the following reactions occur at the surface of the cathode (reduction of water, proton discharge, and reduction of dissolved oxygen):
- the pH of the electrolyte solution is maintained at from about 3 to about 7, or from about 5 to about 7, using hydrochloric acid or ammonium hydroxide.
- the electrolyte solution can be maintained slightly acidic, for example, at a level of from about 5 to about 6. This slightly acidic environment allows for the partial dissolution of the CPP to occur in equilibrium with the precipitation and deposition processes.
- the present technology provides placing the implants in a bath containing the electrolyte solution and rotating the implants during application of the electrical potential.
- the present technology also provides for larger scale processes for making a plurality of medical implants having discrete regions of a calcium phosphate phase deposited thereon. It is envisioned that the process can treat from 2 up to 70 or more implants at one time, depending upon the size and surface area of the implants, as well as the desired electrochemical deposition parameters, including the available power supply.
- the process can include preparing an electrolyte solution comprising calcium ions and phosphate ions having a concentration ratio of calcium:phosphate of about 1.7: 1 as previously described.
- a plurality of implants is then placed into the electrolyte solution, or bath. Any debris on the implant surface may lead to uncoated areas. Accordingly, the implants can optionally be cleaned prior to the deposition process, for example using an appropriate ultrasonic type wash.
- the electrolyte solution is provided in an inner bath container that is placed or disposed within an appropriate outer bath container.
- the outer bath container can be provided with circulating water to maintain a consistent temperature of the inner bath, for example, at about ambient temperature or alternatively about 37 °C.
- Each implant comprises at least one area having an electroconductive surface which, in various embodiments, includes a metallic area or surface. These electroconductive surfaces are appropriately connected and used as the cathodes for cathodic polarization.
- a constant electrical potential is applied between the cathodes and the electrolyte solution, wherein the electrical potential has a constant current density of from about 10 to about 50 mA/cm .
- the electrical potential can be applied for a period of time of from about 1 to about 20 minutes depending on the remaining deposition parameters and desired amount of hydroxyapatite deposition.
- the process includes electrochemically depositing a plurality of discrete regions of needle-shaped hydroxyapatite crystals onto the electroconductive surfaces.
- the implants can be appropriately rotated during the application of electrical potential, depending on the amount of hydrogen bubbling that may occur.
- the implants can be removed and sent to a rinsing station.
- the implants can also be sent to an appropriate anodizing station.
- Such an anodizing bath may be provided including deionized water, trisodium phosphate dodecahydrate, and di-potasium hydrogen phosphate at ambient temperature.
- the electrochemical deposition process may be carried out by cathodic polarization in a number of successive, repeated process cycles.
- a process cycle may include cathodic polarization in one or more successive steps, in certain embodiments during at least two discrete intervals of time, with identical or different (increased or decreased) constant current densities, and a rinsing and/or drying phase following thereon.
- a disc of Ti6A14V having a radius of about 0.5 inches and a thickness of 0.25 inches is prepared with a smooth machine finish, cleaned in an ultrasonic bath, and rinsed with distilled water. The thickness portion is masked and the disc sample is placed into an electrolyte solution at ambient temperature including 150 ml each of a stock solution of CaCl 2 and ⁇ 4 ⁇ 2 ⁇ 0 4 in concentrations of 33 mM and 20 mM, respectively. Deionized water is added providing a 3 L total volume solution having a final concentration of 1.67 mM calcium ions and 1.0 mM phosphate ions. The pH is adjusted to 5.1 using hydrochloric acid.
- electrochemical deposition is carried out by means of galvanostatic polarization under cathodic current flow at a current density of about 40 mA/cm in order to provide a high flux of ions toward the cathode.
- cathodic polarization is complete and the sample is removed and rinsed with deionized water. Electron microscopic examination reveals a plurality of discrete but homogenous regions of CPP having needle like morphology as shown in Figure 1. Further IR-spectroscopic investigations provide proof that the discrete crystalline mineral phase comprises hydroxyapatite.
- a disc of Ti6A14V is prepared as in Example 1.
- the disc sample is placed into an electrolyte solution at ambient temperature including 15 ml each of a stock solution of CaCl 2 and ⁇ 4 ⁇ 2 ⁇ 0 4 in concentrations of 33 mM and 20 mM, respectively.
- Deionized water is added providing a 3 L total volume solution having a final concentration of 0.167 mM calcium ions and 0.1 mM phosphate ions.
- the pH is adjusted to 6.4 using ammonium hydroxide.
- electrochemical deposition is carried out by means of galvanostatic polarization under cathodic current flow at a current density of about 20mA/cm in order to provide a high flux of ions toward the cathode.
- cathodic polarization is complete and the sample is removed and rinsed with deionized water.
- Electron microscopic examination reveals a plurality of discrete but homogenous regions of CPP having needle like morphology as shown in Figure 2. Further IR-spectroscopic and X- ray diffraction investigations provide proof that the discrete crystalline mineral phase comprises hydroxyapatite.
- a disc of Ti6A14V is prepared as in Example 1.
- the disc sample is placed into an electrolyte solution at ambient temperature including 15 ml each of a stock solution of CaCl 2 and NH 4 H 2 P0 4 in concentrations of 33 mM and 20 mM, respectively.
- Deionized water is added providing a 3 L total volume solution having a final concentration of 0.167 mM calcium ions and 0.1 mM phosphate ions.
- the pH is adjusted to 6.4 using ammonium hydroxide.
- electrochemical deposition is carried out by means of galvanostatic polarization under cathodic current flow at a current density of about 30mA/cm in order to provide a high flux of ions toward the cathode.
- cathodic polarization is complete and the sample is removed and rinsed with deionized water.
- Electron microscopic examination reveals a plurality of discrete but homogenous regions of CPP having needle like morphology as shown in Figure 3. Further IR-spectroscopic and X- ray diffraction investigations provide proof that the discrete crystalline mineral phase comprises hydroxyapatite.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/581,483 US20110089041A1 (en) | 2009-10-19 | 2009-10-19 | Methods of depositing discrete hydroxyapatite regions on medical implants |
| PCT/US2010/053138 WO2011049915A2 (en) | 2009-10-19 | 2010-10-19 | Methods of depositing discrete hydroxyapatite regions on medical implants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP2491167A2 true EP2491167A2 (en) | 2012-08-29 |
| EP2491167B1 EP2491167B1 (en) | 2019-07-10 |
Family
ID=43795000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP10773461.8A Active EP2491167B1 (en) | 2009-10-19 | 2010-10-19 | Methods of depositing discrete hydroxyapatite regions on medical implants |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20110089041A1 (en) |
| EP (1) | EP2491167B1 (en) |
| WO (1) | WO2011049915A2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9376759B2 (en) | 2010-09-14 | 2016-06-28 | Michigan Technological University | Compositions, methods and devices for generating nanotubes on a surface |
| HUP1300343A2 (en) * | 2013-05-27 | 2014-11-28 | Bay Zoltan Koezhasznu Nonprofit Kft | Method for production of biocompatibile metal implant with antimicrobal feature and the metal implant |
| CN103938246A (en) * | 2014-04-25 | 2014-07-23 | 浙江大学 | Electrochemical method for preparing strontium-doped hydroxyapatite ridge rodlike structure coating on titanium surface |
| CN103966578B (en) * | 2014-05-09 | 2016-01-27 | 哈尔滨工程大学 | Method for constructing hydroxyapatite superhydrophobic film layer on the surface of magnesium alloy |
| US10687956B2 (en) | 2014-06-17 | 2020-06-23 | Titan Spine, Inc. | Corpectomy implants with roughened bioactive lateral surfaces |
| DE102015101626B4 (en) | 2015-02-04 | 2019-06-27 | Kulzer Gmbh | Coating of dental prosthetic surfaces with a distinct layer of a synthetic hydroxyapatite |
| TWI726940B (en) | 2015-11-20 | 2021-05-11 | 美商泰坦脊柱股份有限公司 | Processes for additively manufacturing orthopedic implants |
| CN106282975B (en) * | 2016-07-27 | 2019-01-18 | 华南理工大学 | In the super-hydrophobic film layer of hydroxyapatite and method of Mg alloy surface preparation and application |
| EP3493769B1 (en) | 2016-08-03 | 2022-03-30 | Titan Spine, Inc. | Titanium implant surfaces free from alpha case and with enhanced osteoinduction |
| CN109758605B (en) * | 2019-02-25 | 2022-12-06 | 青岛科技大学 | Fine acicular hydroxyapatite micro-nanostructure coating on the surface of magnesium alloy and its preparation method |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2691627A (en) * | 1952-02-07 | 1954-10-12 | Scovill Manufacturing Co | Method of producing decorated aluminum articles |
| US3954568A (en) * | 1970-01-30 | 1976-05-04 | Xerox Corporation | Electroforming an endless flexible seamless xerographic belt |
| US4709690A (en) * | 1986-04-21 | 1987-12-01 | Habley Medical Technology Corporation | Implantable blood flow and occlusion pressure sensing sphincteric system |
| JPS63305590A (en) * | 1987-06-05 | 1988-12-13 | Ube Ind Ltd | Manufacturing equipment for printed wiring board substrates |
| US5080455A (en) * | 1988-05-17 | 1992-01-14 | William James King | Ion beam sputter processing |
| US5055318A (en) * | 1988-10-11 | 1991-10-08 | Beamalloy Corporation | Dual ion beam ballistic alloying process |
| US5310464A (en) * | 1991-01-04 | 1994-05-10 | Redepenning Jody G | Electrocrystallization of strongly adherent brushite coatings on prosthetic alloys |
| US5242706A (en) * | 1991-07-31 | 1993-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Laser-deposited biocompatible films and methods and apparatuses for producing same |
| US5807407A (en) * | 1992-05-04 | 1998-09-15 | Biomet, Inc. | Medical implant device and method for making same |
| US5843741A (en) * | 1994-08-01 | 1998-12-01 | Massachusetts Insitute Of Technology | Method for altering the differentiation of anchorage dependent cells on an electrically conducting polymer |
| DE19504386C2 (en) * | 1995-02-10 | 1997-08-28 | Univ Dresden Tech | Process for the production of a graded coating from calcium phosphate phases and metal oxide phases on metallic implants |
| US6095148A (en) * | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| DK173338B1 (en) * | 1996-08-29 | 2000-07-31 | Danfoss As | Process for electrochemical phosphating of metal surfaces, especially of stainless steel, with CaZnPO4 by cold flow of metal |
| JPH10102288A (en) * | 1996-09-24 | 1998-04-21 | Queen Mary & Westfield College | Coating method with calcium phosphate compound |
| DE19643555A1 (en) * | 1996-10-24 | 1998-04-30 | Univ Dresden Tech | Metallic object with a thin multiphase oxide layer and process for its production |
| US6261322B1 (en) * | 1998-05-14 | 2001-07-17 | Hayes Medical, Inc. | Implant with composite coating |
| JP4457230B2 (en) * | 1999-03-19 | 2010-04-28 | 明義 尾坂 | Surface treatment method for medical implant material |
| US6322588B1 (en) * | 1999-08-17 | 2001-11-27 | St. Jude Medical, Inc. | Medical devices with metal/polymer composites |
| US6206924B1 (en) * | 1999-10-20 | 2001-03-27 | Interpore Cross Internat | Three-dimensional geometric bio-compatible porous engineered structure for use as a bone mass replacement or fusion augmentation device |
| JP4091728B2 (en) * | 2000-03-27 | 2008-05-28 | 京セラ株式会社 | Bioimplant material and its manufacturing method |
| JP2003533276A (en) * | 2000-05-16 | 2003-11-11 | レンセラール ポリテクニック インスティチュート | Electrically conductive nanocomposites for biomedical applications |
| DE10029520A1 (en) * | 2000-06-21 | 2002-01-17 | Merck Patent Gmbh | Coating for metallic implant materials |
| US7819861B2 (en) * | 2001-05-26 | 2010-10-26 | Nuortho Surgical, Inc. | Methods for electrosurgical electrolysis |
| DE10158302A1 (en) * | 2000-11-16 | 2002-07-25 | Univ Berlin Tech | Electrolytic coating of metal implants with bio-active materials containing calcium phosphate, maintains implant cathodic in aqueous calcium phosphate |
| US7014749B2 (en) * | 2000-12-28 | 2006-03-21 | Board Of Regents Of The University Of Nebraska | Electrolytic deposition of coatings for prosthetic metals and alloys |
| ATE399571T1 (en) * | 2001-06-06 | 2008-07-15 | Biomet Merck Gmbh | APATITE COATED METALLIC MATERIAL, METHOD FOR THE PRODUCTION AND USE THEREOF |
| AU2002322323A1 (en) * | 2001-06-25 | 2003-01-08 | Massachusetts Institute Of Technology | Bioerodible conducting materials |
| SE522749C2 (en) * | 2002-03-04 | 2004-03-02 | Cerbio Tech Ab | Surface coating process, surface coating device and biocompatible coating |
| US7645262B2 (en) * | 2002-04-11 | 2010-01-12 | Second Sight Medical Products, Inc. | Biocompatible bonding method and electronics package suitable for implantation |
| US7142909B2 (en) * | 2002-04-11 | 2006-11-28 | Second Sight Medical Products, Inc. | Biocompatible bonding method and electronics package suitable for implantation |
| CA2501822C (en) * | 2002-10-08 | 2012-02-21 | Osteotech, Inc. | Coupling agents for orthopedic biomaterials |
| US6884335B2 (en) * | 2003-05-20 | 2005-04-26 | Novellus Systems, Inc. | Electroplating using DC current interruption and variable rotation rate |
| US7001672B2 (en) * | 2003-12-03 | 2006-02-21 | Medicine Lodge, Inc. | Laser based metal deposition of implant structures |
| US7666522B2 (en) * | 2003-12-03 | 2010-02-23 | IMDS, Inc. | Laser based metal deposition (LBMD) of implant structures |
| US7374642B2 (en) * | 2004-01-30 | 2008-05-20 | Deutchman Arnold H | Treatment process for improving the mechanical, catalytic, chemical, and biological activity of surfaces and articles treated therewith |
| US9523144B2 (en) * | 2004-01-30 | 2016-12-20 | Beamalloy Reconstructive Medical Products, Llc | Orthopaedic implants having self-lubricated articulating surfaces designed to reduce wear, corrosion, and ion leaching |
| US7998568B2 (en) * | 2004-06-25 | 2011-08-16 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Bioceramic coated apparatus and method of forming the same |
| CN100439569C (en) * | 2004-07-06 | 2008-12-03 | 厦门大学 | Electrochemical preparation method of nano-ordered hydroxyapatite coating |
| US8114264B2 (en) * | 2005-02-10 | 2012-02-14 | Brookhaven Science Associates | Method of electroplating a conversion electron emitting source on implant |
| US8266780B2 (en) * | 2005-04-21 | 2012-09-18 | Biomet Manufacturing Corp. | Method and apparatus for use of porous implants |
| US7279664B2 (en) * | 2005-07-26 | 2007-10-09 | Boston Scientific Scimed, Inc. | Resonator for medical device |
| US20070048452A1 (en) * | 2005-09-01 | 2007-03-01 | James Feng | Apparatus and method for field-injection electrostatic spray coating of medical devices |
| US7635447B2 (en) * | 2006-02-17 | 2009-12-22 | Biomet Manufacturing Corp. | Method and apparatus for forming porous metal implants |
| US20070233133A1 (en) * | 2006-02-24 | 2007-10-04 | Cohen Taylor S | Bone-Evacuating and Valve-Exiting Resector and Method of Using Same |
| US20070224244A1 (en) * | 2006-03-22 | 2007-09-27 | Jan Weber | Corrosion resistant coatings for biodegradable metallic implants |
| US20070239256A1 (en) * | 2006-03-22 | 2007-10-11 | Jan Weber | Medical devices having electrical circuits with multilayer regions |
| US20080015578A1 (en) * | 2006-07-12 | 2008-01-17 | Dave Erickson | Orthopedic implants comprising bioabsorbable metal |
| ITMI20071083A1 (en) * | 2007-05-28 | 2008-11-29 | Fin Ceramica Faenza Spa | PROCESS FOR COATING A SURFACE OF A METAL ELEMENT TO INCREASE THE OSTEOINTEGRATION AND PROSTHETIC DEVICE THAT INCLUDES THAT ELEMENT |
| US20100047434A1 (en) * | 2008-08-21 | 2010-02-25 | Biomet Manufacturing Corp. | Fabrication of monolithic zones on porous scaffold |
-
2009
- 2009-10-19 US US12/581,483 patent/US20110089041A1/en not_active Abandoned
-
2010
- 2010-10-19 EP EP10773461.8A patent/EP2491167B1/en active Active
- 2010-10-19 WO PCT/US2010/053138 patent/WO2011049915A2/en not_active Ceased
Non-Patent Citations (1)
| Title |
|---|
| See references of WO2011049915A2 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011049915A2 (en) | 2011-04-28 |
| WO2011049915A3 (en) | 2013-01-03 |
| US20110089041A1 (en) | 2011-04-21 |
| EP2491167B1 (en) | 2019-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2491167B1 (en) | Methods of depositing discrete hydroxyapatite regions on medical implants | |
| Kar et al. | Electrodeposition of hydroxyapatite onto nanotubular TiO2 for implant applications | |
| US9738980B2 (en) | Metal treatment | |
| Ryu et al. | Biomimetic apatite induction of P-containing titania formed by micro-arc oxidation before and after hydrothermal treatment | |
| CN102793948A (en) | Biomedical calcium phosphate/zinc oxide nano-rod array composite coating on surface of medical metal and preparation method thereof | |
| US6544288B2 (en) | Biocompatible titanium implant for medical use | |
| Zhang et al. | Electrochemical properties of Ti3+ doped Ag-Ti nanotube arrays coated with hydroxyapatite | |
| Krasicka-Cydzik | Anodic layer formation on titanium and its alloys for biomedical applications | |
| CN108939155A (en) | A kind of magnesium-based tissue engineering material antimicrobial coating and preparation method thereof | |
| Morejón-Alonso et al. | Electrochemical deposition of Sr and Sr/Mg-co-substituted hydroxyapatite on Ti-40Nb alloy | |
| KR100922686B1 (en) | Biomaterial manufacturing method and biomaterial formed therefrom | |
| CN103088383A (en) | Electrochemical method for preparing citric acid-hydroxyapatite/zirconia transition coating on surface of biomedical titanium | |
| CN103120805A (en) | Bioactive surface coating of biomedical degradable magnesium alloy and preparation method thereof | |
| TWI532883B (en) | Titanium or titanium alloy having antibacterial surface and method for manufacturing the same | |
| Ungan et al. | Investigation of MgO effect on bioactivity of coatings produced by MAO | |
| CN114732961A (en) | Magnesium endosteal implant drug-loaded chitosan/zinc apatite coating and preparation method thereof | |
| Hernandez-Montelongo et al. | Cyclic calcium phosphate electrodeposition on porous silicon | |
| Xiao et al. | Low-temperature fabrication of titania layer on 3D-printed 316L stainless steel for enhancing biocompatibility | |
| Sun et al. | Surface modification of Ti6Al4V alloy for implants by anodization and electrodeposition. | |
| Park et al. | Bioactive Calcium Phosphate Coating on Sodium Hydroxide‐Pretreated Titanium Substrate by Electrodeposition | |
| AU2021102400A4 (en) | Method for preparing a strontium-doped calcium-phosphorus compound film with a nano-ordered structure | |
| Zanca et al. | Co-deposition and characterization of hydroxyapatite-chitosan and hydroxyapatite-polyvinylacetate coatings on 304 SS for biomedical devices | |
| CN115029752B (en) | A kind of preparation method suitable for the composite coating of bone implant magnesium or magnesium alloy | |
| JP6783465B2 (en) | Medical bioabsorbable member and its manufacturing method | |
| Saleh et al. | Effect of UV rrradiation on apatite deposition on anodised TiO2 coating formed under mixed acid solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20120515 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: SEWING, ANDREAS Inventor name: GUPTA, GAUTAM |
|
| DAX | Request for extension of the european patent (deleted) | ||
| R17D | Deferred search report published (corrected) |
Effective date: 20130103 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BIOMET MANUFACTURING, LLC |
|
| 17Q | First examination report despatched |
Effective date: 20150917 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C25D 5/18 20060101AFI20181218BHEP Ipc: C25D 9/08 20060101ALI20181218BHEP Ipc: C25D 5/48 20060101ALI20181218BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20190123 |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1153661 Country of ref document: AT Kind code of ref document: T Effective date: 20190715 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602010059956 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: DR. GRAF AND PARTNER AG INTELLECTUAL PROPERTY, CH |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20190710 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1153661 Country of ref document: AT Kind code of ref document: T Effective date: 20190710 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191010 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191010 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191111 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191011 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20191110 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20200224 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602010059956 Country of ref document: DE |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG2D | Information on lapse in contracting state deleted |
Ref country code: IS |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191019 |
|
| 26N | No opposition filed |
Effective date: 20200603 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20191031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191031 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20191019 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20101019 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190710 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20221101 Year of fee payment: 13 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230526 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231031 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20251010 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20251013 Year of fee payment: 16 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20251014 Year of fee payment: 16 |